A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Everolimus (Primary) ; Ribociclib (Primary)
- Indications Duodenal cancer; Gastric cancer; Malignant thymoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 27 Feb 2018 Last checked against Clinicaltrials.gov record.
- 20 Feb 2018 Planned number of patients changed from 42 to 41.
- 20 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium.